In our recent article [1], we did not declare several potential competing interests relevant to this work. We apologize for this omission and would like to disclose the following information: Dr. Janigro has received royalty payments from Roche Diagnostics and holds a patent on S100B for its use as a serum marker for blood-brain barrier leakage. The study was partly supported by Roche Diagnostics. The company does not currently develop any products related to the results described in the article. Reference: 1. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, Janigro D (2010) Extracranial sources of S100B do not affect serum levels. PLoS ONE 5(9): e12691. doi:10.1371/journal.pone.0012691
Citation: Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, et al. (2010) Correction: Extracranial Sources of S100B Do Not Affect Serum Levels. PLoS ONE 5(10): 10.1371/annotation/bdcb41f2-a320-4401-a6ab-86e71738597e. https://doi.org/10.1371/annotation/bdcb41f2-a320-4401-a6ab-86e71738597e
Published: October 29, 2010
Copyright: © 2010 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.